Skip to main content

BrightSpring Health Services, Inc.

For the period ended Mar 31, 2025. Filed May 2, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 2, 2025

BTSG$72.49+4.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Shareholders' Equity

(In thousands, except share data)

Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · NoncontrollingInterest · Total
Shares · Amount
Balances at December 31, 2024174,245,990$1,742$1,866,850$(222,155)$1,418$—$1,647,855
Net income (loss) (1)———29,542—(125)29,417
Other comprehensive loss, net of tax————(3,287)—(3,287)
Share-based compensation——15,681———15,681
Exercise of stock options36,253—345———345
Issuance of common stock for settlement of RSUs1,052,53611(11)————
Tax effect of net share settlement of equity awards(151,345)(1)(2,766)———(2,767)
Balances at March 31, 2025175,183,434$1,752$1,880,099$(192,613)$(1,869)$(125)$1,687,244
Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · NoncontrollingInterest · Total
Shares · Amount
Balances at December 31, 2023117,857,055$1,179$771,336$(200,319)$12,544$670$585,410
Net loss (1)———(45,750)—(152)(45,902)
Other comprehensive income, net of tax————10,571—10,571
Share-based compensation——24,848———24,848
Derecognition of redeemable noncontrolling interest——14,981———14,981
Issuance of common stock on initial public offering, net (2)53,333,334533655,952———656,485
Proceeds from stock purchase contract issued under tangible equity units, net (3)——321,611———321,611
Balances at March 31, 2024171,190,389$1,712$1,788,728$(246,069)$23,115$518$1,568,004

(1) Net loss to the Company for the three months ended March 31, 2025 and 2024 excludes$(407) and$(483), respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.

(2) Issuance of common stock on initial public offering is presented net of underwriting discounts and commissions, and offering-related expenses of $36.8 million.

(3) Proceeds from stock purchase contract issued under tangible equity units is presented net of underwriting discounts and commissions of $9.1 million.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.